Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2017
At a glance
- Drugs MDGN 201 (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Medgenics
- 10 Jun 2017 Biomarkers information updated
- 05 Jun 2017 Status changed from completed to discontinued.
- 26 Sep 2016 Status changed from active, no longer recruiting to completed.